1. Session 5: Invasive, tracheostomy ventilation in MND
We have permission to use image – but not for sharing on social media.

2. MND Statistics Death is almost always due to respiratory failure
as a consequence of respiratory muscle
weakness and/or repeated chest infections.
‘respiratory’ is written 97 times in the NICE 2016 Summary Guidance (383 uses in the full guidance)
Burkhardt, C. et al Cause of Death in MND

3. NIV in MND
NIV improves survival with maintenance of, and improvement in, quality of life, significantly more than neuroprotective therapy (in those without severe bulbar dysfunction).
In patients with severe bulbar impairment, NIV improves sleep-related symptoms, but is unlikely to confer a large survival advantage.
Increasing non-RCT evidence and expert opinion that cough augmentation helps in MND.
non-invasive ventilation is written 76 times and cough 16 times in the full NICE MND Guidance 2016.

4. Tracheostomy in MND
Little in the literature about long term ventilation in MND via tracheostomy.
What little there is shows a mortality advantage, improved QoL (for patient) and increased risk of sudden death.
Not surprising, the 2016 NICE Guidance, doesn't give any advice on when, how or where to use it in the management of MND.
In fact tracheostomy is mentioned zero times in the guidance.

5. Tracheostomy in MND
Despite lack of evidence, long term tracheostomy ventilation is used in patients with MND.
Inability to manage 24 hour ventilation with non-invasive interfaces.
Could be argued that MPV and using a variety of interface could rule this out.
We have consent to use image but not to share.

6. Tracheostomy in MND
Despite lack of guidance/evidence long term tracheostomy ventilation is used in patients with MND.
Inability to manage 24 hour ventilation with non-invasive interfaces.
Could be argued that MPV and using a variety of interface could rule this out.
Severe bulbar involvement with inability to maintain adequate ventilation despite NIV and cough augmentation, particularly those with upper motor neuron/CNS bulbar hypertonicity.
Bach et al suggests patients with ALS need ‘trachs’ when spO2 falls below 95% permanently despite optimal NIV and Cough Assist. 80% of these patients are trached or dead within 2 months.

7. Evidence to support T-NIV in MND
Good 1-year survival rate in MND, respiratory problems being the main cause of hospitalisation but not of death.
Sudden death was the main cause of death and only one patient died from respiratory causes.

8. Summary of pilot national audit (2017)
around 9% of patients in specialist centres have TV for MND, a lot more than anecdotally reported.
more men than women have TV 26 male v 12 female
possibly younger patients, mean age 56 years: Range 26-78
post TV is instituted urgently.
appears to be safe and extends length of life
sudden death is high around 45%
mean inpatient stay is shorter than expected, particularly in electives
most patients go home with skilled carer package
more comprehensive audit to follow soon
(Palmer et al 2018, UK Based Tracheostomy Ventilation in Motor Neurone Disease: A Multi-Centre Review. Thorax 2017;72:A28.